Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
New England Journal of Medicine · 2026-01 · 394 (1) · 13-26
DOI: 10.1056/nejmoa2512071 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, 2026-01. Verfasst von Wenfeng Fang und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cente…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Camptothecin, Carcinoma, Non-Small-Cell Lung, Immunoconjugates. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, NIH HHS, Noncommunicable Chronic Diseases-National Science and Technology Major Project.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center f…
- Department of Thoracic Medical Oncology, Hunan Cancer Hospital/Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Medical Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Respiratory Medicine, First Affiliated Hospital of Nanchang University, Nanchang, China.
- Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
ORCID-Profile: Xiangjiao Meng, Jiuwei Cui, Yongchang Zhang
Förderung
- National Natural Science Foundation of China
- NIH HHS
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Zitieren
APA
Fang, W., Wu, L., Meng, X., Yao, Y., Zuo, W., Yao, W., Xie, Y., Zhang, Y., Cui, J., Zhang, Y., Li, X., Zhuang, W., Fang, J., Wang, Q., Jiang, W., Li, K., Bai, Y., Luo, Y., Ma, F., …, & Zhang, L. (2026). Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC. New England Journal of Medicine, 394(1), 13-26. https://doi.org/10.1056/nejmoa2512071
Vancouver
Fang W, Wu L, Meng X, Yao Y, Zuo W, Yao W, et al. Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC. New England Journal of Medicine. 2026;394(1):13-26. doi:10.1056/nejmoa2512071
BibTeX
@article{Fang2026,
author = {Fang, Wenfeng and Wu, Lin and Meng, Xiangjiao and Yao, Yu and Zuo, Wei and Yao, Wenxiu and Xie, Yanyan and Zhang, Yu and Cui, Jiuwei and Zhang, Yongchang and Li, Xingya and Zhuang, Wu and Fang, Jian and Wang, Qiming and Jiang, Wei and Li, Kai and Bai, Yuju and Luo, Yongzhong and Ma, Fang and Yu, Yan and Zheng, Wei and Liu, Zhentian and Yang, Bin and Ma, Rui and Fang, Yong and Yang, Runxiang and Jiang, Liyan and Hu, Jie and Yang, Jiacheng and Diao, Yina and Jin, Xiaoping and Ge, Junyou and Yang, Yunpeng and Zhang, Li},
title = {Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {1},
pages = {13--26},
doi = {10.1056/nejmoa2512071}
}
EUVIMED